文献速递胸部肿瘤支持与姑息治疗

COVID-19与疫苗接种对实体恶性肿瘤患者长期生存的影响:全国性队列研究

Impact of COVID-19 and vaccination on long-term survival in patients with solid malignancies: A nationwide cohort study.
PubMed 文献 · Eur J Cancer · 2026-03-30

中位随访48.6个月,mRNA疫苗接种者长期死亡风险低于载体疫苗或未接种者(OR 0.41,95%CI 0.28-0.61,P<0.0001),免疫检查点抑制剂治疗者获益最明显,肺癌中mRNA疫苗联合免疫治疗结局更优(18.9% vs 31.1%;OR 0.45,95%CI 0.20-0.98,P=0.036)。

要点

  • mRNA疫苗与实体瘤COVID-19存活者长期死亡风险降低独立相关。
  • 免疫检查点抑制剂治疗者生存获益最明显,肺癌中联合mRNA疫苗结局更优。
  • 多变量回归与倾向评分匹配分析结果一致。

核心结论

  • 在实体恶性肿瘤且COVID-19住院存活患者中,mRNA疫苗接种与长期生存改善独立相关。

研究设计与样本

  • 全国性回顾性真实世界队列研究,使用保加利亚卫生部联合信息门户数据。
  • 采用多变量logistic回归和倾向评分匹配校正人口学与临床混杂因素,遵循ESMO-GROW指南。

主要发现

  • 中位随访48.6个月,mRNA疫苗组中位OS为43.6个月,载体疫苗组34.9个月,未接种组34.5个月。
  • mRNA疫苗相比载体疫苗或未接种的长期死亡OR为0.41(95%CI 0.28-0.61,P<0.0001)。
  • 免疫检查点抑制剂治疗者生存获益最明显,肺癌中mRNA疫苗联合免疫治疗结局更优(18.9% vs 31.1%;OR 0.45,95%CI 0.20-0.98,P=0.036)。
  • 多变量与倾向评分匹配分析结果一致。

临床怎么用

  • 对实体恶性肿瘤且COVID-19住院存活患者,mRNA COVID-19疫苗可能带来长期生存获益。
  • 接受免疫检查点抑制剂治疗者,尤其肺癌患者,mRNA疫苗与免疫治疗联合可能结局更优。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term impact of SARS-CoV-2 infection and vaccination in patients with solid malignancies remains incompletely defined, particularly with respect to long-term oncologic outcomes and interactions with systemic anticancer therapies. METHODS: We conducted a nationwide, retrospective real-world cohort study using data from the Bulgarian Ministry of Health's United Information Portal. Adult patients (n = 1797) with solid malignancies who survived hospitalization for COVID-19 between March 2020 and June 2022 were included and followed through November 2025. Overall survival (OS) was evaluated according to vaccination status, vaccine platform (mRNA vs vector-based), primary tumor localization, and oncologic treatment modality. Multivariable logistic regression and propensity score matching were applied to adjust for demographic and clinical confounders. The study was conducted in accordance with ESMO-GROW guidelines. RESULTS: After a median follow-up of 48.6 months, mRNA-based vaccination was independently associated with lower long-term mortality (median OS, 43.6 months) compared with vector-based vaccination (34.9 months) or no vaccination (34.5 months) (OR, 0.41; 95% CI, 0.28-0.61; P < 0.0001). The survival benefit was most pronounced among patients receiving immune checkpoint inhibitors, particularly in lung cancer, where combined mRNA vaccination and immunotherapy was associated with superior outcomes (18.9% vs 31.1%; OR, 0.45; 95% CI, 0.20-0.98; P = 0.036). Results were consistent across multivariable and propensity score-matched analyses. CONCLUSIONS: In this large national real-world cohort with nearly five years of follow-up, mRNA-based COVID-19 vaccination was independently associated with improved long-term survival in patients with solid malignancies who survived COVID-19 hospitalization, supporting durable protective effects and suggesting a potential immunomodulatory interaction with immune checkpoint inhibition.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dimitrov G, Argirova R, Valkov T, et al. Impact of COVID-19 and vaccination on long-term survival in patients with solid malignancies: A nationwide cohort study. Eur J Cancer. 2026. PMID: 41930856. doi:10.1016/j.ejca.2026.116708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。